| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary targets of Tirucallol include HIV-1 reverse transcriptase and inflammatory pathways. It inhibits HIV-1 reverse transcriptase with an IC50 of 3.8 µM. Tirucallol also has topical anti-inflammatory properties, suppressing ear edema in mouse models and inhibiting nitrite production in LPS-stimulated macrophages.
|
|---|---|
| ln Vitro |
In vitro, Tirucallol has been shown to inhibit HIV-1 reverse transcriptase with an IC50 of 3.8 µM. It also inhibits nitrite production in lipopolysaccharide-stimulated macrophages. The compound's anti-inflammatory activity has been confirmed in various in vitro models.
|
| ln Vivo |
In vivo, Tirucallol suppresses ear edema in mouse models. It has topical anti-inflammatory properties. The compound's anti-inflammatory effects have been demonstrated in various animal models. However, specific detailed in vivo protocols are limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Tirucallol involve measuring its inhibition of HIV-1 reverse transcriptase activity. The assay uses a purified HIV-1 reverse transcriptase enzyme and a template-primer substrate. The incorporation of radiolabeled nucleotides into the growing DNA chain is measured. The compound is incubated with the enzyme and substrate at varying concentrations to determine the IC50 (3.8 µM).
|
| Cell Assay |
In vitro cell-based assays for Tirucallol are performed using macrophages. Cells are treated with the compound and stimulated with lipopolysaccharide (LPS). The production of nitrite is measured using the Griess assay. The compound's anti-inflammatory effects are assessed by measuring the reduction in nitrite production.
|
| Animal Protocol |
In vivo animal experiments for Tirucallol are conducted using mouse models of ear edema. The compound is applied topically, and ear swelling is measured. The compound's anti-inflammatory effects are evaluated by measuring the reduction in ear edema.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Tirucallol indicate that it has a molecular weight of 426.72 and a molecular formula of C30H50O. The CAS number is 514-46-5. The IUPAC name is (13alpha,14beta,17alpha,20S)-5alpha-Lanosta-8,24-Dien-3beta-Ol. It is a solid with a purity of ≥98%.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Tirucallol are limited. As a natural triterpenoid, it is generally considered safe at moderate doses. However, its safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
Tirucarol is a triterpenoid compound. It has been reported to be found in tea plants, soybeans, and other organisms with relevant data.
Other information: Tirucallol is a pentacyclic triterpenoid alcohol isolated from various plants. It has anti-inflammatory and anti-HIV activities. The compound is also known as Tirucalladienol. Its CAS number is 514-46-5. |
| Molecular Formula |
C30H50O
|
|---|---|
| Molecular Weight |
426.72
|
| Exact Mass |
426.386
|
| CAS # |
514-46-5
|
| PubChem CID |
101257
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
498.9±44.0 °C at 760 mmHg
|
| Melting Point |
133 - 134.5 °C
|
| Flash Point |
221.1±20.7 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.530
|
| LogP |
11
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
767
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@@H](CCC=C(C)C)[C@@H]1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
| InChi Key |
CAHGCLMLTWQZNJ-HGKXYCPESA-N
|
| InChi Code |
InChI=1S/C30H50O/c1-20(2)10-9-11-21(3)22-14-18-30(8)24-12-13-25-27(4,5)26(31)16-17-28(25,6)23(24)15-19-29(22,30)7/h10,21-22,25-26,31H,9,11-19H2,1-8H3/t21-,22-,25-,26-,28+,29-,30+/m0/s1
|
| Chemical Name |
(3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-((S)-6-methylhept-5-en-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
NSC403164 NSC 403164 NSC-403164Tirucallol(+)-Tirucallol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~23.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3435 mL | 11.7173 mL | 23.4346 mL | |
| 5 mM | 0.4687 mL | 2.3435 mL | 4.6869 mL | |
| 10 mM | 0.2343 mL | 1.1717 mL | 2.3435 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
